|
|
 |
|
Viewing report
|
|
|
|
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas
Bioseeker, Sep 2007, Pages: 500
This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the leukemia and lymphoma field. This extensive 500+ pages report compiles and analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.
The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.
The report further give an in depth analysis in two important key oncology areas; Breast- and Prostate cancer. And provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
Decoding Big Pharma’s R&D Strategy in Oncology in numbers:
- Includes references to more than 250 drugs and 600 clinical/preclinical trials
- Addresses the competitive situation on more than 80 different cancer indications, including supportive care indications
- Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer
- The included competitive landscape between the five big pharma includes more than 200 companies related to cancer drug development
- Last five years of deals and alliances in oncology, including almost a hundred different key deals and alliances
- Target analysis of 119 drug targets in oncology, including molecular function of target, target localization, type of compound for targeting, targets affecting signaling pathways etc
- Drug compound analysis by cancer indications
Gain insight into the current challenges and commercial opportunities associated with leukemia and Lymphoma therapy. Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in leukemia and Lymphoma R&D, and the results of clinical trials to date.
Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. In this report, the author does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to understand the complex field of leukemia therapeutics. Provide one of the most comprehensive coverage of the R&D trends to set the future leukemia marketplace. The author presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 85 drug candidates in phase II or III stage of development and more than 50 companies are involved in the development of these drugs.
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin’s lymphoma (NHL). The lymphoma market is a complex topic and several pitfalls await actors not well prepared. The author will guide thru this field and bring structure and knowledge enables our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan.
Already today it is clear that rituximab has generated substantial revenues for the companies involved in its development. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
The leukemia and lymphoma scope of this report
- Thorough examination of status and impact of several novel drugs in development
- Discussion of the challenges in current and future treatment strategies
Customers who bought this item also bought
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
Antibody Drug Targets and Special Focus on Leukemias & Lymphomas
Chronic Leukemias - Curative Intent Raises The Bar
Acute Leukemias - Persistent Unmet Needs Confer Significant Commercial Opportunity
Triple Analysis: Decoding Big Pharmas R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas
Drugs of Tomorrow: Leukemia - Chemopotentiators Will Drive Growth in the Acute Leukemia Markets
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
|
|
|
